Consumption of anthocyanin-rich Queen Garnet plum juice reduces platelet activation related thrombogenesis in healthy volunteers

The anti-thrombotic properties of an anthocyanin-rich Queen Garnet plum juice (QGPJ) and anthocyanin-free prune juice (PJ) were studied in this randomised, double-blind, crossover trial. Twenty-one healthy subjects (M = 10, F = 11) consumed QGPJ, PJ or placebo, 200 mL/day for 28-days followed by a 2-week wash-out period. Only QGPJ supplementation inhibited platelet aggregation induced by ADP (2.1 s, P = 0.03); reduced plasma-fibrinogen (<7.5%, P = 0.02) and malondialdehyde levels, a plasma biomarker of oxidative stress ( P = 0.016). PJ supplementation increased plasma hippuric acid content ( P = 0.018). QGPJ or PJ supplementation did not affect blood cell counts, lipid profile, or inflammation markers. Our findings suggest that QGPJ but not PJ has the potential to significantly attenuate thrombosis by reducing platelet activation/hyper-coagulability and oxidative stress

Consumption of anthocyanin-rich Queen Garnet plum juice reduces platelet activation related thrombogenesis in healthy volunteers

The anti-thrombotic properties of an anthocyanin-rich Queen Garnet plum juice (QGPJ) and anthocyanin-free prune juice (PJ) were studied in this randomised, double-blind, crossover trial. Twenty-one healthy subjects (M = 10, F = 11) consumed QGPJ, PJ or placebo, 200 mL/day for 28-days followed by a 2-week wash-out period. Only QGPJ supplementation inhibited platelet aggregation induced by ADP (2.1 s, P = 0.03); reduced plasma-fibrinogen (<7.5%, P = 0.02) and malondialdehyde levels, a plasma biomarker of oxidative stress (P = 0.016). PJ supplementation increased plasma hippuric acid content (P = 0.018). QGPJ or PJ supplementation did not affect blood cell counts, lipid profile, or inflammation markers. Our findings suggest that QGPJ but not PJ has the potential to significantly attenuate thrombosis by reducing platelet activation/hyper-coagulability and oxidative stress

Anthocyanin supplementation inhibits secretion of pro-inflammatory cytokines in overweight and obese individuals

Chronic low-grade inflammation in obese and overweight individuals is associated with an increased risk of type II diabetes and cardiovascular disease. The current trial investigated the anti-inflammatory properties of anthocyanin (ACN) supplementation in lean, overweight and obese individuals. Fifteen lean, ten overweight and ten obese participants consumed ACN (320 mg/day) for 28 days along with their usual diet. ACN supplementation significantly decreased blood plasma levels of CCL2 in the lean, overweight and obese groups (p < 0.0001, p < 0.0001 and p < 0.01 respectively). Additionally, significantly decreased levels of IL-6 in the obese group (p < 0.05) were also observed post-ACN supplementation. In conclusion, these results demonstrate the anti-inflammatory potential of ACN and suggest the supplementation of ACN as a complementary therapeutic agent for reducing chronic inflammation in obese and overweight individuals.</p